LTH-A Inhibitors
The class of LTH-A inhibitors comprises a wide range of compounds, each designed to target specific enzymes or signaling nodes that directly or indirectly affect LTH-A function. For example, Wortmannin, a PI3K inhibitor, targets the p110α catalytic subunit, hindering the conversion of PIP2 to PIP3. This reduced PIP3 formation hampers Akt activation, which, if LTH-A functions downstream of Akt, leads to reduced LTH-A activity. Similarly, LY294002 inhibits PI3K by competing with ATP for binding on the catalytic site, achieving a comparable effect on LTH-A by the same logic.
Rapamycin and NVP-BEZ235, on the other hand, focus on inhibiting mTOR. Rapamycin forms a complex with FKBP12, which inhibits mTOR and subsequently suppresses the phosphorylation of downstream molecules like p70S6K and 4E-BP1. NVP-BEZ235 inhibits both PI3K and mTOR, offering a dual mechanism for modulating LTH-A if it is involved in these pathways. Compounds like U0126 and PD98059 target the MEK-ERK axis, offering another angle of modulation for LTH-A if it is regulated by ERK1/2. Through these specific mechanisms, the LTH-A inhibitors provide a robust approach to controlling this protein's activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor that binds to the p110α catalytic subunit. By binding to this subunit, it prevents PI3K from phosphorylating PIP2 to PIP3, which is crucial for Akt activation. This lack of Akt activation would lead to less activation or modulation of LTH-A if it is downstream of Akt. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR by binding to its complex partner FKBP12. The inhibition of mTOR subsequently suppresses the phosphorylation of p70S6K and 4E-BP1. If LTH-A is regulated through these downstream molecules of mTOR, its activity will be altered. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 competes with ATP for binding on the catalytic site of PI3K. This prevents the conversion of PIP2 to PIP3 and thereby hampers Akt activation. If LTH-A is influenced by Akt activity, it will be indirectly inhibited or modulated. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits MEK, blocking the activation of downstream ERK. If LTH-A is directly or indirectly regulated by ERK activation, its activity can be modulated by this inhibitor. | ||||||
GDC-0941 | 957054-30-7 | sc-364498 sc-364498A | 5 mg 10 mg | $188.00 $199.00 | 2 | |
GDC-0941 is a potent inhibitor of PI3K. It specifically blocks p110α and p110δ, preventing PIP2 to PIP3 conversion and subsequent Akt activation. If LTH-A is downstream of Akt, its activity will be compromised. | ||||||
BEZ235 | 915019-65-7 | sc-364429 | 50 mg | $211.00 | 8 | |
NVP-BEZ235 inhibits both PI3K and mTOR, reducing the activation of downstream molecules like Akt and 4E-BP1. If LTH-A functions in pathways downstream of these molecules, it will be modulated. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase. If LTH-A is involved in a pathway downstream of EGFR, its activity can be impacted. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib inhibits both EGFR and HER2/neu, affecting downstream signaling. If LTH-A is downstream or influenced by these receptor tyrosine kinases, its function will be altered. | ||||||
Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
Cobimetinib inhibits MEK, thereby affecting the downstream activation of ERK. If LTH-A is modulated by ERK, its activity will be indirectly altered by this inhibitor. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib inhibits MEK1 and MEK2, preventing the phosphorylation and activation of downstream ERK1/2. If LTH-A is directly or indirectly regulated by these, its activity will be altered. | ||||||